Cbay stock forecast.

Dec 1, 2023 · According to the issued ratings of 12 analysts in the last year, the consensus rating for CymaBay Therapeutics stock is Buy based on the current 11 buy ratings and 1 strong buy rating for CBAY. The average twelve-month price prediction for CymaBay Therapeutics is $22.27 with a high price target of $34.00 and a low price target of $12.00.

Cbay stock forecast. Things To Know About Cbay stock forecast.

Forecast . Price target. 24.08 0.00 0.00%. The 12 analysts offering 1 year price forecasts for CBAY have a max estimate of — and a min estimate of —. Analyst rating. Based on 13 analysts giving stock ratings to CBAY in the past 3 months. EPS. Annual Annual Quarterly Quarterly More MoreCymaBay Therapeutics Inc. (CBAY) stock forecast and price target. Find the latest CymaBay Therapeutics Inc. CBAY analyst stock forecast, price target, and recommendation trends with in-depth ... TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comStock Price Forecast. The 22 analysts offering 12-month price forecasts for Thermo Fisher Scientific Inc have a median target of 519.50, with a high estimate of 600.00 and a low estimate of 435.00 ...UBS has decided to maintain its Buy rating of CymaBay Therapeutics (NASDAQ:CBAY) and raise its price target from $18.00 to $25.00. Shares of CymaBay Therapeutics are trading up 7.26% over the last ...

Jun 30, 2023 · CBAY Stock Forecast: Positive Outlook and Analyst Consensus for CymaBay Therapeutics Inc. CBAY stock has been performing well in recent months, with positive forecasts from analysts. On June 30, 2023, the 10 analysts offering 12-month price forecasts for CBAY had a median target of $15.00, indicating a potential increase of 35.14% from the last ... CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) NEWARK, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced …

Cymabay Therapeutics Inc Stock Price Forecast, "CBAY" Predictons for2025Based on 10 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $24.40 with a high forecast of $33.00 and a low forecast of $20.00. The average price target represents a 29.93% change from the last price of $18.78. Highest Price Target $33.00. Average Price Target $24.40.

CBAY enters Uptrend as Momentum indicator ascends above 0 level This indicator may be signaling that CBAY's price has momentum to move higher, since its current price …According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecastsThe average twelve-month price prediction for CymaBay Therapeutics is $22.27 with a high price target of $34.00 and a low price target of $12.00. Learn more on CBAY's analyst rating history. Do Wall Street analysts like CymaBay Therapeutics more than its competitors?Wall Street Stock Market & Finance report, prediction for the future: You'll find the Coterra Energy share forecasts, stock quote and buy / sell signals below. According to present data Coterra Energy's CTRA shares and potentially its market environment have been in bearish cycle last 12 months (if exists).

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary ...

Is Cymabay Therapeutics (NASDAQ:CBAY) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, ...

Over the past 3 months, 14 analysts have published their opinion on CymaBay Therapeutics CBAY stock. These analysts are typically employed by large Wall Street banks and tasked with understanding ...Find the latest AFC Gamma, Inc. (AFCG) stock quote, history, news and other vital information to help you with your stock trading and investing.Reported on 11/6/23. Get the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more …Stock analysis for Cymabay Therapeutics Inc (CBAY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Xenon Pharmaceuticals Inc. 28.97. +0.24. +0.84%. Get CymaBay Therapeutics Inc (CBAY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Their PTGX share price targets range from $32.00 to $38.00. On average, they expect the company's share price to reach $35.25 in the next twelve months. This suggests a possible upside of 109.4% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts.CymaBay Therapeutics Inc. (CBAY) stock forecast and price target. Find the latest CymaBay Therapeutics Inc. CBAY analyst stock forecast, price target, and recommendation trends with in-depth ... Nov 13. 4.17%. $94.57. Check if AHPI Stock has a Buy or Sell Evaluation. AHPI Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Allied Healthcare Products News.This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0280 between high and low, or 8.46%.For the last week the stock has had daily average volatility of 7.18%.. Our recommended stop-loss: $0.325 (-3.60%) (This stock …Stock analysis for Cymabay Therapeutics Inc (CBAY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

The current CymaBay Therapeutics [ CBAY] share price is $17.90. The Score for CBAY is 74, which is 48% above its historic median score of 50, and infers lower risk than normal. CBAY is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.

Analyst Forecast. According to 12 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is $22.64, which is an increase of 18.35% from the latest price.Stock Price Forecast. The 23 analysts offering 12-month price forecasts for Nokia Oyj have a median target of 4.39, with a high estimate of 7.60 and a low estimate of 3.49. The median estimate ...Overview Stock Screener Earnings Calendar Sectors Nasdaq CBAY U.S.: Nasdaq CymaBay Therapeutics Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 15, 2023 7:49 p.m. EST...AC Immune S.A. analyst ratings, historical stock prices, earnings estimates & actuals. ACIU updated stock price target summary.Dec 1, 2023 · The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low. CBAY Stock Forecast: Positive Outlook and Analyst Consensus for CymaBay Therapeutics Inc. CBAY stock has been performing well in recent months, with positive forecasts from analysts. On June 30, 2023, the 10 analysts offering 12-month price forecasts for CBAY had a median target of $15.00, indicating a potential increase of 35.14% from the last ...In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.

Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...

Based on short-term price targets offered by 11 analysts, the average price target for CymaBay Therapeutics Inc. comes to $24.45. The forecasts range from a low of $20.00 to a high of $34.00.

Cymabay Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction. ... CBAY Related stocks. Symbol 3M %Chg ; CBAY +35.42% : Cymabay Therapeutics: RDY ...Traders may consider buying the stock or exploring call options. I backtested 91 similar cases where CBAY's Momentum Indicator exceeded 0, and 78 of them led t This indicator may be signaling that CBAY's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or ... Find real-time MCOM - micromobility.com inc stock quotes, company profile, news and forecasts from CNN Business.A high-level overview of CymaBay Therapeutics, Inc. (CBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Traders may consider buying the stock or exploring call options. I backtested 91 similar cases where CBAY's Momentum Indicator exceeded 0, and 78 of them led t This indicator may be signaling that CBAY's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or ...He kept his outperform rating on CBAY stock and raised his price target to 20 from 18. Notably, CymaBay stock has a best-possible Relative Strength Rating of 99, according to IBD Digital. This ...The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...CymaBay Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CBAY updated stock price target summary.Xenon Pharmaceuticals Inc. 28.97. +0.24. +0.84%. Get CymaBay Therapeutics Inc (CBAY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Creative Medical Technology Holdings Inc have a median target of 30.00, with a high estimate of 30.00 and a low estimate ... 3 Wall Street research analysts have issued 1-year price targets for Tecnoglass' shares. Their TGLS share price targets range from $43.00 to $54.00. On average, they anticipate the company's stock price to reach $48.20 in the next year. This suggests a possible upside of 30.2% from the stock's current price.CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce ...

6 analysts have issued 12 month price objectives for Spruce Biosciences' shares. Their SPRB share price targets range from $4.00 to $10.00. On average, they expect the company's share price to reach $7.67 in the next year. This suggests a possible upside of 463.7% from the stock's current price.EBAY Regular Dividend: EBAY will begin trading ex-dividend today with a $0.25 dividend payable to shareholders of record as of 12/01/23. Quote. Profile. News. Charts. Forecasts. Financials ...Find the latest AFC Gamma, Inc. (AFCG) stock quote, history, news and other vital information to help you with your stock trading and investing.Instagram:https://instagram. spyx stockgoogle stock price prediction 2030fig etfwcda loan Apr 26, 2023 · The stock is selling for $9.87 and its $13.89 average price target suggests a 12-month upside potential of ~41%. (See CBAY stock forecast ) Cerevel Therapeutics ( CERE ) largest prop trading firmsexpi stock forecast Ra Medical Systems, Inc (NYSE:RMED) released its quarterly earnings results on Monday, November, 15th. The company reported ($57.50) earnings per share for the quarter, missing the consensus estimate of ($39.50) by $18.00. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.70 million. free nft Over the past 3 months, 14 analysts have published their opinion on CymaBay Therapeutics CBAY stock. These analysts are typically employed by large Wall Street banks and tasked with understanding ...See the latest CymaBay Therapeutics Inc stock price (CBAY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.